News
FDA extends the PDUFA date for tenapanor for the control of serum phosphorus in patients with CKD on dialysis.-Ardelyx, Inc.
Condition: Hyperphosphataemia
Type: drug
Register for free access to this exclusive healthcare learning resource
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Already a subscriber? Log in